Analyst Price Target is $3.00
▲ +339.88% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OpGen in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 339.88% upside from the last price of $0.68.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in OpGen. This Buy consensus rating has held steady for over two years.
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
Read More